Navigating the Regulatory Landscape

Date: September 2015

As global Regulatory Agencies continue to evolve their policies to match the pace of development in cell and gene therapy, it’s essential for both academic and commercial scientists to understand the implications of these changes on their path to translation and product commercialisation.

We bring you regulatory updates and insight from three major bodies:
  • EMA
  • FDA
  • Japan
With Japan championing an innovative and radical approach to regulating cell therapies and regenerative medicines, we ask our industry experts to share their insight with us on the commercial impact of these changes – not only within Japan but for international companies looking to collaborate/partner and take advantage of this regulatory environment. The Spotlight also includes a series of interviews and webinars with commercial leaders who share with us their experience in navigating their cell and gene therapy products through the regulatory landscape.